
Opinion|Videos|January 14, 2025
The Impact of Targeted Gene Therapy and Nadofaragene Firadenovec on BCG-Unresponsive NMIBC
Author(s)Max Kates, MD
A panelist discusses how targeted gene therapy, particularly nadofaragene firadenovec, represents a paradigm shift in BCG-unresponsive NMIBC treatment.
Advertisement
Episodes in this series

- How has the introduction of targeted gene therapy changed the way you approach managing BCG-unresponsive NMIBC?
- What are the broader implications of using gene therapy to treat BCG-unresponsive NMIBC, and how does nadofaragene firadenovec fit into this landscape overall?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
FDA approves cefepime and zidebactam for complicated UTI
3
Enzalutamide associated with greater cognitive decline than darolutamide in advanced prostate cancer
4
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
5









